Actionable insights straight to your inbox


Biocept Launches Liquid Biopsy Research Kits for Cancer Gene Mutations

Target Selector kits are research-use-only (RUO), to enable labs to leverage Biocept's patented assay technology for liquid biopsy testing
The full IPO calendar is available at Ranked by size of IPO, largest first. (1) Real estate finance Based in New York, NY, Ladder Capital ($LADR) scheduled a $225 million IPO on the
Biocept (BIOC) is an early-stage cancer diagnostics company that develops and commercializes proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, tests utilizing a
At we show that the Medical sector is 9.8% overvalued. The Medical Products industry is 4.2% overvalued. The Medical Services industry is 9.1% overvalued. The Medical